Our expression profiling of both human and mouse T-ALL samples, and publicly available human T-LBL [34] and mouse T-ALL expression data [33], suggest NAMPT expression is downregulated in T cell malignancies, likely explaining the efficacy of FK866 that we observed in these samples. This evidence concerns the gene NAMPT and acute lymphoblastic leukemia.